Study (authors/title)	Year published	Number of participants	Type of study	Inclusion criteria	Intervention	Comparator	Primary endpoints	Notes
Ridker et al.,3 CANTOS	2017	10,061	dbRCT	Previous MI, hsCRP ≥2 mg/l	Canakinumab 50, 100 and 150 mg	Placebo	Nonfatal MI, nonfatal stroke and CV mortality
Ridker et al.,19 JUPITER	2008	17,802	dbRCT	No CVD history, LDL-C < 3.4 mmol/l and hsCRP ≥ 2 mg/l	Rosuvastatin 20 mg	Placebo	First MACE
Wang et al.11	2016	106	RCT	CHD + hyperlipidemia	Ezetimibe 10 mg + rosuvastatin 10 mg	Rosuvastatin 10 mg	New/recurrent MI, unstable angina, CV mortality and stroke
Nicholls et al.,12 SATURN	2011	1039	dbRCT	One vessel with >20% stenosis + target vessel <50% obstructed	Atorvastatin 80 mg	Rosuvastatin 40 mg	Percent change in atheroma volume	Also measured MACE
Ridker et al.,20 AFCAPS/TexCAPS (substudy)	2001	5742	dbRCT	Average TC and LDL, below average HDL	Lovastatin 20 mg, adjusted to 40 mg as necessary	Placebo	First acute coronary event
Heljić et al.17	2009	95	RCT	T2DM without CHD	Simvastatin 40 mg	Placebo	Acute MI, revascularisation and stroke
Sever et al.,21 ASCOT-LLA (substudy)	2013	2772	Randomised open-label, blinded-endpoint	Hypertensive patients with 3+ CVD risk factors but no MI or angina history	Atorvastatin 10 mg	Placebo	CV mortality, nonfatal MI, revascularisation and stroke
Yusuf et al.,23 HOPE-3	2016	12,705	dbRCT	At least one CVD risk factor (men) or at least two (women)	Rosuvastatin 10 mg	Placebo	CV mortality, nonfatal MI, nonfatal stroke, cardiac arrest, HF, revascularisation
Soedamah-Muthu et al.,22 Collaborative Atorvastatin Diabetes Study	2015	2322	RCT	T2DM	Atorvastatin 10 mg	Placebo	MACE
Watanabe et al.,13 CHERRY	2017	193	Non-blinded RCT	Stable angina, PCI	Eicosapentaenoic acid 1800 mg + pitavastatin 4 mg	Pitavastatin 4 mg	Change in coronary plaque tissue characteristics	Also measured MACE
Im et al.14	2018	2000	dbRCT	PCI within 12 months, aspirin monotherapy	Atorvastatin 40 mg	Pravastatin 20 mg	MACE
Kitas et al.,18 TRACE-RA	2019	3002	dbRCT	RA	Atorvastatin 40 mg	Placebo	MACE
Taguchi et al.,15 REAL-CAD	2018	13,054	Randomised open-label, blinded-endpoint	Stable CAD	Pitavastatin 4 mg	Pitavastatin 1 mg	CV mortality, nonfatal stroke, nonfatal MI, unstable angina
Bhatt et al.,16 REDUCE-IT	2019	8179	dbRCT	Established CVD, diabetes or other risk factors	Icosapent ethyl 2 g twice daily	Placebo	MACE
Gilham et al.,24 SUSTAIN/ASSURE	2016	499	dbRCT	Stable CAD (SUSTAIN), coronary angiography (ASSURE)	RVX-208 100 mg twice daily + SOC	Placebo + SOC	MACE